Diverse function of aromatase and the N-terminal sequence deleted form

Journal of Steroid Biochemistry and Molecular Biology

Volumn 61, Issue 3-6, 1997, Pages 117-126

  Osawa, Yoshio ^a   Higashiyama, Tadayoshi ^a   Toma, Yoshiro ^a   Yarborough, Carol ^a  

^a HAUPTMAN WOODWARD MEDICAL RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

7 ETHOXYCOUMARIN; AROMATASE; COCAINE; CYTOCHROME P450; ESTRADIOL; OXYGENASE;

BINDING SITE; CONFERENCE PAPER; CONTROLLED STUDY; DELETION MUTANT; ENZYME ACTIVITY; ENZYME BINDING; ESCHERICHIA COLI; ESTROGEN METABOLISM; FEMALE; HUMAN; HUMAN TISSUE; ISOTOPE LABELING; PLACENTA; PROTEIN EXPRESSION; REACTION ANALYSIS;

ESCHERICHIA COLI;

EID: 0031120071     PISSN: 09600760     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-0760(96)00217-8     Document Type: Conference Paper

References (33)

1. Osawa Y., Higashiyama T., Fronckowiak M., Yoshida N., Yarborough C. Aromatase. J. Steroid Biochem. 27:1987;781-789.
2. Osawa Y., Yoshida N., Fronckowiak M., Kitawaki J. Immunoaffinity purification of aromatase cytochrome P450 from human placental microsomes, metabolic switching from aromatization to 1β- and 2β-monohydroxylation, and recognition of aromatase isozymes. Steroids. 50:1987;11-28.
3. Yoshida N., Osawa Y. Purification of human placental aromatase cytochrome P450 with monoclonal antibody and its characterization. Biochemistry. 30:1991;3003-3010.
4. Osawa Y., Higashiyama T., Shimizu Y., Yarborough C. Multiple functions of aromatase and the active site structure: aromatase is the placental estrogen 2-hydroxylase. J. Steroid Biochem. Molec. Biol. 44:1993;469-480.
5. Osawa Y., Higashiyama T., Yarborough C. Difference in the 2-/4-regioselectivity of catecholestrogen biosynthesis in ovary and placenta. Dallas, TX IXth International Congress on Hormonal Steroids. 1994;117.
6. Osawa Y., Higashiyama T., Yarborough C. Difference in the 2-/4-regioselectivity of catecholestrogen biosynthesis in ovary and placenta. Dallas, TX IXth International Congress on Hormonal Steroids. 1994;C106.
7. Shimizu Y., Yarborough C., Osawa Y. Competitive product inhibition of aromatase by natural estrogens. J. Steroid Biochem. Molec. Biol. 44:1993;651-656.
8. Kono S. Specific radioimmunoassay and physiological significance of unconjugated 2-hydroxyestrone and 2-hydroxyestradiol-17β in human blood. Acta Obstet. Gynaecol. Japan. 34:1982;794-800.
9. Berg F.D., Kuss E. Serum concentration and urinary excretion of "classical" estrogens, catecholestrogens and 2-methoxyestrogens in normal human pregnancy. Arch. Gynecol. Obstet. 251:1992;17-27.
10. Kadohama N., Yarborough C., Zhou D., Chen S., Osawa Y. Kinetic properties of aromatase mutants Pro308Phe, Asp 309Asn, and Asp309Ala and their interactions with aromatase inhibitors. J. Steroid Biochem. Molec. Biol. 43:1992;693-701.
11. Kadohama N., Zhou D., Chen S., Osawa Y. Catalytic efficiency of expressed aromatase following site-directed mutagenesis. Biochim. Biophys. Acta. 1163:1993;195-200.
12. Chen S., Zhou D., Swiderek K.M., Kadohama N., Osawa Y., Hall P.F. Structure-function studies of aromatase. J. Steroid Biochem. Molec. Biol. 44:1993;347-356.
13. Toma Y., Higashiyama T., Zhou D., Yarborough C., Chen S., Osawa Y. Multifunctionality of aromatase cytochrome P450 (CYP19) expressed in Escherichia coli. Dallas, TX IXth International Congress on Hormonal Steroids. 1994;147.
14. Toma Y., Higashiyama T., Zhou D., Yarborough C., Chen S., Osawa Y. Multifunctionality of aromatase cytochrome P450 (CYP19) expressed in Escherichia coli. Dallas, TX IXth International Congress on Hormonal Steroids. 1994;D132.
15. Osawa Y., Higashiyama T., Yarborough C., Zhou D., Chen S. N-terminal sequence deleted forms of human aromatase cytochrome P450. San Francisco, CA 10th International Congress of Endocrinology. 1996;873.
16. Osawa Y., Higashiyama T., Yarborough C., Zhou D., Chen S. N-terminal sequence deleted forms of human aromatase cytochrome P450. San Francisco, CA 10th International Congress of Endocrinology. 1996;P3-P475.
17. Washida N., Kitawaki J., Higashiyama T., Matsui S., Osawa Y. Preparation of an activity-inhibiting monoclonal antibody against human placental aromatase cytochrome P450. Steroids. 61:1996;126-132.
18. Toma Y., Higashiyama T., Yarborough C., Osawa Y. Diverse functions of aromatase: O-deethylation of 7-ethoxycourmarin. Endocrinology. 137:1996;3791-3796.
19. Greenlee W.F., Poland A. An improved assay of 7-ethoxycoumarin O-deethylase activity: induction of hepatic enzyme activity in C57BL/6J and DBA/2J mice by phenobarbital, 3-methylcholanthrene and 2,3,7,8-tetracholrodibenzo-p-dioxin. J. Pharmacol. Exp. Ther. 205:1978;596-605.
20. Jacobson M., Levin W., Poppers P.J., Wood A.W., Conney A.H. Comparison of the O-dealkylation of 7-ethoxycoumarin and the hydroxylation of benzo[a]pyrene in human placenta. Clin. Pharmacol. Ther. 16:1974;701-710.
21. Pelkonen O., Moilanen M.L. The specificity and multiplicity of human placental xenobiotic-metabolizing monooxygenase system studied by potential substrates, inhibitors and gel electrophoresis. Med. Biol. 57:1979;306-312.
22. Kaelin A.C., Cummings A.J. Differential inhibition of human placental monooxygenase activity: evidence for multiple forms of 7-ethoxycoumarin O-deethylase. Biochem. Pharmacol. 33:1984;505-508.
23. Pasanen M., Haaparanta T., Sundin M., Sivonen P., Vakakangas K., Raunio H., Hines R., Gustafsson J., Pelkonen O. Immunochemical and molecular biological studies on human placental cigarette smoke-inducible cytochrome P450-dependent monooxygenase activities. Toxicology. 62:1990;175-187.
24. Meigs R.A. The constitutive 7-ethoxycoumarin O-deethylase of human placental microsomes: relationship to the intermediary steps in steroid aromatization. Life Sci. 46:1990;321-327.
25. Osawa Y. Mechanism of aromatization. Scow R.O. Endocrinology Proceedings of 4th International Congress of Endocrinology. Washington, D. C. 1972 International Congress Series Series No. 273. 1973;814-819 Excerpta Medica Amsterdam.
26. Osawa Y., Yarborough C., Osawa Y. Norethisterone, a major ingredient of the contraceptive pill, is a suicide inhibitor of estrogen biosynthesis. Science. 215:1982;1249-1251.
27. Osawa Y., Osawa Y., Yarborough C., Borzynski L. Irreversible inhibitors of oestrogen biosynthesis (aromatase). Biochem. Soc. Trans. 11:1983;656-659.
28. Osawa Y.: Compositions containing 5α-dihydro-19-norethisterone for in vivo inhibition of endocrine-dependent conditions in mammals. United States Patent, 1989, 4,829,059 (Appl. 1987).
29. Osawa Y.: Compositions containing 5α-dihydro-19-norethisterone and derivatives thereof for in vivo inhibition of aromatase. United States Patent, 1990, 4,978,658 (Appl. 1988).
30. Wiggins R., Rolsten C., Ruiz B., Davis C. Pharmacokinetics of cocaine: basic studies of route, dosage, pregnancy and lactation. Neurotoxicology. 10:1989;367-381.
31. Ahmed M., Zhou D., Maulik D., Elderfrawi M. Characterization of cocaine binding site in human placenta. Life Sci. 46:1990;553-561.
32. Critchley H., Woods S., Barson A., Richardson T., Lieberman B. Fetal death in utero and cocaine abuse. Case report. Br. J. Obstet. Gynecol. 95:1988;195-196.
33. Kitawaki J., Yoshida N., Osawa Y. An enzyme-linked immunosorbent assay for quantitation of aromatase cytochrome P450. Endocrinology. 124:1989;1417-1423.